1 min read
Alcami recently contributed to an eBook produced by Drug Development and Delivery. The eBook, titled "Analytical Testing in Drug Development," features four companies and explains how they each help the pharmaceutical and biotech industries comply with drug development regulatory requirements.
Angela Moore, abuse-deterrence studies subject matter expert at Alcami, contributed to the eBook. Her article focuses on considerations for abuse-deterrent Category 1 studies as well as standard syringeability studies.
"Healthcare professionals around the world are commonly prescribing opioid medications for pain management, generating an inevitable association with abuse and addiction. The Centers for Disease Control and Prevention (CDC) has estimated that, in 2017, over 47,600 Americans died from opioid overdoses. Of these deaths, 35% involved the use of prescription opioid medications."
Related Posts
Designing a CMC Strategy for Accelerated Biologics Development
Customizing Analytical Testing Programs to Meet Accelerated Timelines
Editorial: Analytical Testing - Contractors Take on the Challenge of Complex Molecules
Alcami contributed to a special feature in Drug Development and Delivery magazine titled ...